Ralimetinib (LY2228820) dimesylate

Ralimetinib (LY2228820) dimesylate is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.
Supplier Selleck Chemicals
Product # S1494
Sku # S1494-50mg
Pricing 50mg, $970.00
Feedback